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Antidepressant utilisation and incidence of weight gain during 
10 years’ follow-up: population based cohort study
Rafael Gafoor,1 Helen P Booth,1,2 Martin C Gulliford1,3
ABSTRACT
OBJECTIVE
To evaluate the long term association between 
antidepressant prescribing and body weight.
DESIGN
Population based cohort study.
SETTING
General practices contributing to the UK Clinical 
Practice Research Datalink, 2004-14.
PARTICIPANTS
136 762 men and 157 957 women with three or more 
records for body mass index (BMI).
MAIN OUTCOME MEASURES
The main outcomes were antidepressant prescribing, 
incidence of ≥5% increase in body weight, and 
transition to overweight or obesity. Adjusted rate 
ratios were estimated from a Poisson model adjusting 
for age, sex, depression recording, comorbidity, 
coprescribing of antiepileptics or antipsychotics, 
deprivation, smoking, and advice on diet.
RESULTS
In the year of study entry, 17 803 (13.0%) men and 
35 307 (22.4%) women with a mean age of 51.5 years 
(SD 16.6 years) were prescribed antidepressants. 
During 1 836 452 person years of follow-up, the 
incidence of new episodes of ≥5 weight gain in 
participants not prescribed antidepressants was 8.1 
per 100 person years and in participants prescribed 
antidepressants was 11.2 per 100 person years 
(adjusted rate ratio 1.21, 95% confidence interval 
1.19 to 1.22, P<0.001). The risk of weight gain 
remained increased during at least six years of follow-
up. In the second year of treatment the number of 
participants treated with antidepressants for one 
year for one additional episode of ≥5% weight gain 
was 27 (95% confidence interval 25 to 29). In people 
who were initially of normal weight, the adjusted 
rate ratio for transition to overweight or obesity was 
1.29 (1.25 to 1.34); in people who were initially 
overweight, the adjusted rate ratio for transition to 
obesity was 1.29 (1.25 to 1.33). Associations may not 
be causal, and residual confounding might contribute 
to overestimation of associations.
CONCLUSION
Widespread utilisation of antidepressants may be 
contributing to long term increased risk of weight 
gain at population level. The potential for weight gain 
should be considered when antidepressant treatment 
is indicated.
Introduction
Obesity is an increasing concern worldwide. Between 
1975 and 2014 the global prevalence of obesity 
increased from 3.2% to 10.8% for men and from 6.4% 
to 14.9% for women.1 The United States and United 
Kingdom have among the highest rates of obesity in the 
world: 69% of US adults are overweight or obese and 
36% are obese,2 and 61% of UK adults are overweight 
or obese, with the prevalence of obesity increasing 
from 15% in 1993 to 26% in 2016.3 Severe obesity is 
strongly associated with socioeconomic inequality in 
both the US and the UK.4 Weight gain and obesity are 
important public health problems, being associated 
with increased risk of chronic disease and mortality.5 6 
Once obesity is established, it is difficult to achieve 
substantial and sustained weight loss.7
Antidepressants are increasingly being prescribed.8 
In a primary care population 23% of 1.5 million 
participants were prescribed an antidepressant on 
at least one occasion between 1995 to 2011.9 The 
number of antidepressant prescriptions issued nearly 
doubled over the same period, although some of the 
increase might be explained by extended duration 
of courses of treatment.9 Obesity is associated with 
depression, which is particularly common in patients 
with severe obesity.10 11 Antidepressant treatment 
may also be associated with weight gain,12 through 
mechanisms that are only partially understood.13 The 
current high prevalence of antidepressant use could 
have potentially important public health impacts 
through the association with body weight gain, but 
the nature of this association is poorly described. 
Although a systematic review of antidepressant use 
and weight gain collated evidence from 116 clinical 
trials and clinical cohort studies,14 fewer than half 
of the studies contributed data for more than three 
months of follow-up and it was not reported how many 
studies included more than 12 months of follow-up. 
The review also drew attention to the heterogeneity 
among different antidepressant drugs, with bupropion 
and fluoxetine being associated with lower weight gain 
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WhAT IS AlReAdy knoWn on ThIS TopIC
Obesity is global and antidepressant use is increasingly widespread
Short term studies suggest strong associations between antidepressant use and 
weight gain
No robust data exist on the long term risks of weight gain or the relative risks of 
weight gain for individual antidepressants
WhAT ThIS STudy AddS
Antidepressant treatment is associated with a sustained increase in risk of 
weight gain over at least five years
Associations with subsequent weight gain appear to vary widely within and 
between antidepressant classes
Risk of weight gain should be considered when antidepressants are to be 
prescribed
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than mirtazapine and nortriptyline.14 Most studies 
have reported on weight change in depressed patients 
treated in clinical settings, but few population based 
studies have investigated the potential population 
impact of widespread antidepressant treatment on 
weight gain. One study evaluated weight change 
after initiation of antidepressant treatment in 5932 
patients registered with the Group Health system in 
Washington state, USA, and found that weight gain 
persisted for at least two years.15 A UK study analysed 
data for 268 patients treated with antidepressants from 
a general practice with 11 994 registered patients, 
and concluded that weight gain persisted during long 
term treatment, with, in some instances, prescriptions 
maintained for several years.16 Another US study 
evaluated weight gain in the 12 months after initiation 
of antidepressant treatment in 22 610 adults treated 
in clinics in New England and found differences in the 
propensity of individual antidepressants to result in 
weight gain.17
In this study we used primary care electronic health 
records to evaluate non-randomised evidence on the 
long term association of antidepressant prescribing 
with weight gain. We also evaluated the associations 
in different subgroups and whether individual 
antidepressant drugs might be associated with greater 
risks of weight gain.
Methods
Data source
We carried out a population based cohort study in the 
UK Clinical Practice Research Datalink (CPRD). The 
CPRD is one of the world’s largest databases of primary 
care electronic health records, with participation 
of about 7% of UK general practices and with 
ongoing collection of anonymised data from 1990. 
The registered active CPRD population is generally 
representative of the UK population in terms of age, 
sex, and regional distribution.18 During 2004-14, 
the annual count of the CPRD registered population 
aged 20 years and older peaked at 3.7 million, with 
a total of 7.1 million participants aged 20 years or 
older registered at any time during the period. Data 
collected into CPRD comprise clinical diagnoses; 
records of clinical measurements, including body mass 
index (BMI) and body weight records taken during 
primary care consultations19; prescriptions; results of 
investigations; and referrals to specialist services.
Participants and cohort selection
The sample was drawn from the population of 2 006 296 
patients registered with general practices participating 
in CPRD between 1 November 2004 and 31 October 
2014 inclusive, who were aged 20 years or older and 
had three or more BMI measurements ever recorded.7 
To provide a sample for analysis, we stratified eligible 
participants according to their first recorded BMI 
measurement (kg/m2): 18.5-24.9 (normal weight), 
25.0-29.9 (overweight), 30.0-34.9 (obese), 35.0-35.9 
(severe obesity), 40.0-44.9 (morbid obesity), and ≥45.0 
(super obesity). Using the “sample” command in Stata, 
we selected a random sample of up to a maximum of 
30 000 participants from each category of BMI and sex, 
resulting in 314 477 participants, for whom data were 
extracted for 314 449 participants. Fewer than 30 000 
women had a BMI of ≥45 and fewer than 30 000 men 
had a BMI of ≥40. We then extracted full CPRD records 
for this sample. In the analysis phase we computed 
additional BMI values from recorded weight and 
height, permitting a greater number of participants to 
be represented in some BMI categories. We excluded 
participants with no BMI records for 1 November 2004 
to 31 October 2014.
Main outcome measures
Antidepressant prescriptions were the exposure 
of interest. We initially classified these according 
to section 4.3 of the British National Formulary,20 
including tricyclic and related antidepressants (TCAs), 
monoamine oxidase inhibitors (MAOIs), selective 
serotonin reuptake inhibitors (SSRIs), serotonin-
noradrenaline (norepinephrine) reuptake inhibitors 
(SNRIs), and other antidepressant drugs. We then 
analysed individual antidepressant drugs: mirtazapine, 
duloxetine, sertraline, venlafaxine, citalopram, 
fluoxetine, escitalopram, trazodone, amitriptyline, 
paroxetine, nortriptyline, and dosulepin.
Body weight was the outcome of interest. We 
evaluated all records of body weight, height, and BMI. 
If a body weight value was recorded that indicated a 
weight increase of ≥5% compared with the previous 
year, we classified the calendar year as being associated 
with weight gain. In the analysis we retained person 
time not associated with recorded body weight values, 
incorporating the assumption that weight gain had 
not occurred. In a sensitivity analysis, we excluded 
person time with no weight records, so as to provide a 
“complete case” analysis.
We included several variables as known 
confounders or effect modifiers in the relation between 
antidepressant use and subsequent weight gain: sex; 
initial BMI category; age; smoking status; coprescribing 
of antiepileptics or antipsychotics; and comorbidities 
of diabetes, coronary heart disease, stroke, cancer, 
and depression. Classifications of presence or absence 
of cancer, coronary heart disease, and stroke were 
recorded clinically, or if the participant had been 
referred to specialist services for management of any 
of these conditions. We classified diabetes as being 
present if the condition had been recorded in the 
dataset clinically, the participant had been prescribed 
a drug for the control of insulin dependent or non-
insulin dependent diabetes, or the participant had 
been referred to a diabetes clinic. Participants were 
classified as depressed in each year of follow-up if they 
were recorded as having depression in a given year.21 
Smoking status was taken from the clinical records, 
or inferred from referrals to smoking cessation clinics 
or from prescriptions of devices or drugs for smoking 
cessation.22 We also included whether participants 
had received advice about weight management or 
diet.23 Deprivation classification was based on fifths 
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of the English index of multiple deprivation (2010), 
which evaluates social and material deprivation across 
seven domains. For subgroup analyses we categorised 
age into 10 year groups.
Statistical analyses
The unit of analysis was person years, with each 
participant’s record being divided into calendar years of 
follow-up. We classified person time for each calendar 
year as “exposed” if one antidepressant prescription or 
more was issued in that year. In univariate analyses, 
we estimated the incidence of ≥5% body weight gain 
per 100 person years for participants treated or not 
treated with antidepressants. The number needed to 
harm (NNH) was computed as the reciprocal of the risk 
difference. We conducted Poisson regression analyses 
using person years as observations. The outcome was 
incidence of ≥5% gain in body weight, the exposure 
was antidepressant use in a year, and the log of person 
time was included as offset. To allow for correlation 
of repeated observations on participants we used 
robust variance estimates. We estimated adjusted rate 
ratios along with confidence intervals. The models 
included the quadratic term age2. The final fully 
adjusted model adjusted for sex, initial BMI category, 
age, age2, diabetes, coronary heart disease, stroke, 
cancer, depression, smoking status, coprescribing 
of antiepileptics or antipsychotics, diet advice, year, 
region of residence, and fifth of deprivation. For 
adjusted analyses, we calculated the NNH by applying 
the adjusted rate ratio to the incidence of weight gain in 
participants not treated with antidepressants, enabling 
estimation of the risk difference and its reciprocal the 
NNH. Forest plots present measures of association 
for subgroups and individual antidepressants and for 
antidepressant classes. To evaluate heterogeneity by 
Table 1 | Characteristics of participants according to antidepressant prescribing. Values are numbers (row percentages) 
unless stated otherwise
Characteristics No Antidepressant Antidepressant
Total 241 609 (82.0) 53 110 (18.0)
Men 118 959 (87.0) 17 803 (13.0)
Women 122 650 (77.7) 35 307 (22.4)
Age group (years):
 20-29 29 597 (84.8) 5305 (15.2)
 30-39 33 260 (80.1) 8247 (19.9)
 40-49 44 955 (78.9) 12 061 (21.2)
 50-59 48 131 (80.1) 11 988 (20.0)
 60-69 46 218 (83.7) 9003 (16.3)
 70-79 29 184 (86.2) 4691 (13.9)
 ≥80 10 264 (85.0) 1815 (15.0)
BMI category (kg/m2):
 14.0-18.4 433 (79.9) 109 (20.1)
 18.5-24.9 44 857 (86.1) 7266 (13.9)
 25.0-29.9 50 264 (85.4) 8620 (14.6)
 30.0-34.9 48 273 (82.9) 9942 (17.1)
 35.0-39.9 45 358 (80.7) 10 828 (19.3)
 40.0-44.9 32 393 (78.0) 9140 (22.0)
 >45.0 20 031 (73.6) 7205 (26.5)
Comorbidity:
 Coronary heart disease 24 122 (81.4) 5516 (18.6)
 Diabetes 42 122 (79.8) 10 682 (20.2)
 Stroke 4903 (74.9) 1645 (25.1)
 Cancer 12 940 (81.9) 2865 (18.1)
 Depression recordings 2036 (12.4) 14 400 (87.6)
Coprescribing:
 Antiepileptic 3730 (62.8) 2211 (37.2)
 Antipsychotic 2412 (38.9) 3794 (61.1)
Smoking status:
 Non-smoker 117 874 (84.2) 22 101 (15.8)
 Former smoker 61 906 (83.5) 12 245 (16.5)
 Current smoker 61 829 (76.7) 18 764 (23.3)
Index of multiple deprivation fifth:
 1st (least deprived) 37 639 (84.2) 7056 (15.8)
 2nd 45 778 (82.9) 9451 (17.1)
 3rd 50 768 (82.0) 11 138 (18.0)
 4th 55 504 (81.5) 12 603 (18.5)
 5th (most deprived) 51 920 (80.1) 12 862 (19.9)
Country:
 England 186 976 (82.7) 39 052 (17.3)
 Northern Ireland 7945 (77.9) 2257 (22.1)
 Scotland 24 389 (79.0) 6472 (21.0)
 Wales 22 299 (80.7) 5329 (19.3)
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both antidepressant class and overall we conducted 
random effects meta-analyses. We used Stata version 
14.224 and R version 3.4.225 for statistical analyses.
Patient involvement
No patients were involved in setting the research 
question or the outcome measures, nor were 
they involved in developing plans for design or 
implementation of the study. We received input 
into the report from Patient and Public Involvement 
representatives who commented on the relevance 
of the design question, the readability of the report, 
and the potential impact of the outcomes on their 
treatment.
Results
The initial cohort comprised 314 449 participants. We 
excluded all person time for 3809 (1.2%) participants 
with insufficient records for analysis; 2404 (0.8%) 
with an ever record of bariatric surgery for treatment 
of obesity; 13 517 (4.3%) with no BMI values recorded 
between 2004 and 2014 or no record of smoking 
status; and person time for women who had given birth 
during a period defined as 280 days (40 weeks) before 
and after the recorded date of delivery. The final sample 
for analysis included 294 719 (93.7%) participants.
Table 1 presents the characteristics of participants 
at their entry to the study according to antidepressant 
prescribing status. Among 294 719 participants, 
53 110 (18.0%) were prescribed antidepressants in 
their first calendar year of study entry. The proportion 
prescribed antidepressants was greater in women 
(22.4%) than in men (13.0%) and was highest between 
the ages of 30 and 59 years. Antidepressant use was 
strongly associated with BMI category, being lowest in 
those of normal body weight (13.9%) and increasing 
with BMI category up to 26.5% in those with a BMI of 
≥45. Antidepressant use was greater in patients with 
comorbidity and coprescriptions, particularly with 
diagnoses of stroke and diabetes or coprescribing of 
antiepileptics or antipsychotics, than in those without. 
Antidepressant use was also associated with current 
smoking and higher deprivation category.
Table 2 presents the distribution of person time for 
the whole sample and for subgroups by covariates, 
together with the number of new cases of ≥5% weight 
Table 2 | Baseline characteristics by antidepressant prescribing and weight gain. Values are frequencies except unless 
stated otherwise
Characteristics
No antidepressant Antidepressant
Person  
years
≥5%  
weight gain
Incidence/ 
100 person years
Person  
years
≥5%  
weight gain
Incidence/ 
100 person years
Total 1 454 909 118 462 8.1 381 543 42 839 11.2
Men 728 208 54 494 7.5 129 862 13 398 10.3
Women 726 701 63 968 8.8 251 680 29 441 11.7
Age group (years):
 20-29 101 633 11 163 11.0 19 792 2993 15.1
 30-39 163 285 15 704 9.6 44 017 6048 13.7
 40-49 252 218 22 289 8.8 79 302 9988 12.6
 50-59 290 131 23 880 8.2 88 597 10 109 11.4
 60-69 314 516 24 403 7.8 78 431 7957 10.1
 70-79 229 011 14 976 6.5 48 182 4065 8.4
 ≥80 104 116 6047 5.8 23 221 1679 7.2
BMI category (kg/m2):
 14.0-18.4 4959 101 2.0 1571 40 2.5
 18.5-24.9 250 546 12 507 5.0 47 916 3269 6.8
 25.0-29.9 329 117 23 307 7.1 67 697 6413 9.5
 30.0-34.9 308 812 23 573 7.6 76 823 7575 9.9
 35.0-39.9 264 974 22 320 8.4 76 047 8172 10.7
 40.0-44.9 176 339 18 110 10.3 59 696 7731 14.0
 ≥45.0 120 163 18 544 15.4 51 793 9639 18.6
Comorbidity:
 Coronary heart disease 172 445 13 471 7.8 49 570 4989 10.1
 Diabetes 314 672 26 708 8.5 100 183 10 704 10.7
 Stroke 37 882 3041 8.0 15 115 1555 10.3
 Cancer 112 346 8048 7.2 30 356 2871 9.5
 Depression recorded 7215 737 10.2 66 660 7740 11.6
Coprescribing:
 Antiepileptic 24 657 2360 9.6 16 240 1993 12.3
 Antipsychotic 14 676 1740 11.9 24 815 3591 14.5
Index of multiple deprivation fifth:
 1st (least deprived) 237 325 17 874 7.5 53 146 5735 10.8
 2nd 280 343 22 523 8.0 69 182 7638 11.0
 3rd 300 334 24 207 8.1 77 382 8503 11.0
 4th 324 533 26 771 8.2 88 440 10 096 11.4
 5th (most deprived) 312 373 27 087 8.7 93 392 10 867 11.6
Current smoker 326 618 27 992 8.6 117 164 13 796 11.8
Diet advice 403 929 48 006 11.9 114 533 18 538 16.0
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gain. Over a 10 year period there was a total of 
1 836 452 person years of follow-up. For 1 454 909 
person years not associated with antidepressant 
use, the incidence of ≥5% weight gain was 8.1 per 
100 person years, whereas for 381 543 person years 
associated with antidepressant use the incidence 
was 11.2 per 100 person years. The unadjusted rate 
ratio was 1.38 (95% confidence interval 1.36 to 1.39, 
P<0.001). Table 2 also presents data for subgroups 
by sex, age, initial BMI, comorbidity, coprescribing, 
deprivation, smoking, and diet advice. While the risk 
of weight gain without antidepressant use decreased 
with age and increased with increasing BMI category, 
the incidence of weight gain was higher for participants 
treated with antidepressants than for those not treated 
with antidepressants across all subgroups.
Figure 1 presents unadjusted and adjusted rate 
ratios for weight increase according to antidepressant 
use, as well as estimates for subgroups of covariates. 
After adjustment for covariates, the rate ratio was 
1.21 (95% confidence interval 1.19 to 1.22, P<0.001) 
indicating that during the entire period of follow-up 
the risk of ≥5% weight gain was 21% higher during 
antidepressant treatment than at other times. The 
absolute risk of weight gain without antidepressant 
use was 8.1 per 100 person years; a rate ratio of 1.21 
is consistent with an absolute risk of weight gain with 
antidepressant use of 9.8 per 100 person years. The 
risk difference of 1.7 per 100 person years is consistent 
with a NNH of 59 (95% confidence interval 57 to 65) 
patient years treated with antidepressants for one 
episode of weight gain, assuming the association is 
causal.
Supplementary table 1 shows the results of a 
sensitivity analysis to evaluate the effect of excluding 
person time in which there were no weight records. 
Weight records were available for 67.1% of person 
years in the antidepressant group and 64.2% of person 
years in the no antidepressant group. Consequently, 
omitting person time with no weight records 
disproportionately reduced the denominator for the 
no antidepressant group leading to a lower adjusted 
rate ratio estimate of 1.16 (1.16 to 1.17). The finding 
that antidepressant use is associated with weight gain 
is robust to varying assumptions about person time 
without weight records.
Adjusted rate ratios for weight gain associated 
with antidepressant treatment were consistent across 
subgroups of age, BMI, region of residence, deprivation 
level, coprescribing of antipsychotics or antiepileptics, 
and smoking status (fig 1). However, rate ratios for 
weight gain tended to be slightly lower for participants 
with diabetes mellitus or coronary heart disease 
compared with those without comorbidity. No similar 
association was seen in those participants with cancer.
Figure 2 presents adjusted rate ratios according to 
years of antidepressant treatment. Participants with 
one or more years of treatment showed an increased 
risk of weight gain that was maintained during six 
years of follow-up. Adjusted rate ratios were 1.46 (1.43 
to 1.49) in the second year of follow-up and 1.48 (1.45 
  Unadjusted
  Adjusted*
Sex
  Male
  Female
Body mass index
  14.0-18.4
  18.5-24.9
  25.0-29.9
  30.0-34.9
  35.0-39.9
  40.0-44.9
  ≥45
Age (years)
  20.0-29.9
  30.0-39.9
  40.0-49.9
  50.0-59.9
  60.0-69.9
  70.0-79.9
  ≥80
Diabetes
  Absent
  Present
Coronary heart disease
  Absent
  Present
Stroke
  Absent
  Present
Cancer
  Absent
  Present
Smoking status
  Non-smoker
  Former smoker
  Current smoker
Antiepileptics
  Absent
  Present
Antipsychotics
  Absent
  Present
Region
  England
  Northern Ireland
  Scotland
  Wales
Deprivation h
  1st (least deprived)
  2nd
  3rd
  4th
  5th (most deprived)
1.38 (1.36 to 1.39)
1.21 (1.19 to 1.22)
1.21 (1.19 to 1.24)
1.21 (1.19 to 1.22)
1.30 (0.89 to 1.89)
1.29 (1.24 to 1.35)
1.26 (1.22 to 1.30)
1.21 (1.17 to 1.24)
1.18 (1.15 to 1.21)
1.22 (1.18 to 1.25)
1.17 (1.14 to 1.20)
1.24 (1.18 to 1.29)
1.27 (1.23 to 1.31)
1.22 (1.19 to 1.25)
1.20 (1.18 to 1.23)
1.17 (1.14 to 1.20)
1.19 (1.15 to 1.23)
1.21 (1.14 to 1.27)
1.23 (1.21 to 1.24)
1.14 (1.12 to 1.17)
1.22 (1.20 to 1.23)
1.15 (1.11 to 1.19)
1.21 (1.19 to 1.22)
1.15 (1.08 to 1.22)
1.21 (1.20 to 1.22)
1.16 (1.11 to 1.21)
1.21 (1.19 to 1.23)
1.17 (1.14 to 1.20)
1.23 (1.21 to 1.26)
1.21 (1.19 to 1.22)
1.13 (1.06 to 1.20)
1.21 (1.19 to 1.22)
1.13 (1.07 to 1.19)
1.21 (1.19 to 1.23)
1.24 (1.18 to 1.30)
1.20 (1.16 to 1.23)
1.18 (1.14 to 1.23)
1.23 (1.20 to 1.27)
1.19 (1.15 to 1.22)
1.20 (1.17 to 1.23)
1.22 (1.19 to 1.25)
1.19 (1.17 to 1.22)
0.9 1.0 1.1 1.2 1.3 1.4
Rate ratio
(95% CI)
Rate ratio
(95% CI)
Fig 1 | Forest plot for association of antidepressant prescribing with ≥5% weight gain 
for whole cohort and subgroups. *Rate ratios were adjusted for sex, body mass index 
category, age, age2, diabetes, coronary heart disease, stroke, cancer, depression, 
smoking status, coprescribing of antiepileptics or antipsychotics, diet advice, year, 
region, and fifth of deprivation
 o
n
 2 April 2020 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.k1951 on 23 May 2018. Downloaded from 
RESEARCH
6 doi: 10.1136/bmj.k1951 | BMJ 2018;361:k1951 | the bmj
to 1.51) in the third year. Adjusted rate ratios then 
declined; from year 7 onwards there was no evidence 
for an increased risk of weight gain. During the second 
year of treatment, the risk of one additional episode of 
≥5% weight gain may be expected for every 27 (25 to 
29) patients treated.
Table 3 shows the association of antidepressant 
treatment with risk of increase in BMI category. In 
people who were initially of normal weight (BMI 
18.5-24.9), the adjusted rate ratio for transition to 
overweight or obesity was 1.29 (1.25 to 1.34); in 
people who were initially overweight (BMI 25.0-29.9), 
the adjusted rate ratio for transition to obesity was 1.29 
(1.25 to 1.33). These secondary analyses confirm that 
antidepressant use might be associated with clinically 
important weight gain when evaluated using different 
categories for weight increase.
A random effects meta-analysis was conducted 
(fig 3) to evaluate heterogeneity within and between 
antidepressant classes. SSRI and TCA classes were 
heterogeneous (I2=92.8%, P<0.001 and I2=75.0%, 
P=0.018, respectively). Weak evidence of heterogeneity 
was found for the SNRI class (venlafaxine and 
duloxetine) (I2=64.3%, P=0.094). Given the 
heterogeneity within classes of antidepressants, the 
relation between individual antidepressants and 
weight gain was explored (figs 3 and 4). Mirtazapine 
appeared to be associated with the greatest adjusted 
rate ratio of weight gain (1.50, 95% confidence interval 
1.45 to 1.56). Figure 4 shows the relative frequencies 
of prescribing compared with the adjusted rate ratio 
for individual antidepressants—in order of frequency 
of use: amitriptyline (25.9%), citalopram (19.8%), 
fluoxetine (16.0%), sertraline (9.0%), venlafaxine 
(6.4%), paroxetine (5.5%), mirtazapine (4.5%), 
dosulepin (3.9%), escitalopram (3.7%), trazodone 
(1.9%), duloxetine (2.1%), and nortriptyline (1.1%).
discussion
This population based cohort study reports data for 
participants registered in primary care who had three 
or more measurements for body mass index (BMI), with 
sampling stratified by BMI category. Analysis reveals a 
high prevalence of exposure to antidepressant drugs. 
Considering the entire period of follow-up (10 years), 
participants who were prescribed an antidepressant 
had an increased risk of ≥5% weight gain compared 
with those who had never been prescribed an 
antidepressant, after allowing for differences in case 
mix. This association was consistently observed across 
a wide range of population subgroups. Participants 
of normal weight showed an increased risk of 
transitioning to overweight or obesity, and overweight 
participants were more likely to become obese if they 
were treated with an antidepressant. The risk of weight 
gain was substantially increased during the second 
and third years of treatment. Less than 12 months’ 
use of antidepressants did not appear to be associated 
with weight gain, but this might be an artefact from 
incomplete data recording. Pharmacological classes of 
antidepressants displayed intraclass heterogeneity for 
later risk of weight gain. Mirtazapine was associated 
with the highest incidence rate ratio of weight 
gain, although the drug was relatively infrequently 
prescribed.
Strengths and limitations of this study
This study used data from a large nationally 
representative primary care database in the United 
Kingdom. Use of electronic health records enabled us 
to comprehensively ascertain whether participants 
had received prescriptions for antidepressants. We 
used clinical records of weight, height, and BMI. These 
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Fig 2 | Adjusted rate ratios for ≥5% weight gain by 
number of years of antidepressant treatment. Rate 
ratios were adjusted for sex, body mass index category, 
age, age2, diabetes, coronary heart disease, stroke, 
cancer, depression, smoking status, coprescribing 
of antiepileptics or antipsychotics, diet advice, year, 
region, and fifth of deprivation. Whiskers represent 95% 
confidence intervals
Table 3 | Association of antidepressant prescription with increase in body mass index (BMI) category. Values are frequencies 
unless stated otherwise
Variables
Initial BMI category (kg/m2)*
18.5-24.9 25.0-29.9 30.0-34.9 35.0.39.9 40.0-44.9
No antidepressant:
 Person years 264 728 309 434 297 714 275 752 192 405
 Increase in BMI category 14 940 18 440 20 205 21 824 16 337
Antidepressant:
 Person years 50 763 64 152 73 014 78 907 66 040
 Increase in BMI category 3751 5265 6562 8028 7095
Unadjusted rate ratio (95% CI) 1.31 (1.26 to 1.36) 1.38 (1.34 to 1.42) 1.32 (1.29 to 1.36) 1.29 (1.25 to 1.32) 1.27 (1.23 to 1.30)
Adjusted rate ratio (95% CI)† 1.29 (1.25 to 1.34) 1.29 (1.25 to 1.33) 1.23 (1.19 to 1.26) 1.22 (1.19 to 1.25) 1.21 (1.17 to 1.24)
*163 542 person years were accounted for by initial BMI categories of <18.5 or ≥45.0.
†Adjusted for age, sex, depression recording, comorbidity, coprescribing of antiepileptics or antipsychotics, deprivation, smoking, and advice on diet.
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measures are not always systematically recorded in 
primary care.19 Infrequent recording of BMI could 
lead to underestimation of associations if weight gain 
occurred but no measurement was taken; conversely, 
confounding of measurement by indication might 
occur if family doctors are more likely to record body 
weight when there has been weight gain. The direction 
of any possible bias from incomplete recording of body 
weight is difficult to anticipate. We initially selected 
participants who had at least three BMI measurements 
recorded, leading to over-representation of those 
with comorbidity; participants with no comorbidities 
being less likely to have BMI recorded than those 
with concurrent illnesses. Patients with comorbidities 
such as diabetes mellitus or coronary heart disease 
may be more likely to be enrolled in self management 
interventions that focus on diet, exercise, and 
weight control and this could modify estimated 
associations. Also, in this non-randomised study, 
residual confounding might lead to bias. Confounding 
by indication might occur if the propensity to be 
prescribed antidepressants is also associated with 
the propensity to gain weight. The present data 
show that 94% of treated patients had a diagnosis 
of depression. However, antidepressant drugs can 
be prescribed for several disorders, and depression 
might not always have been the sole indication for 
prescription. We cannot exclude the possibility that 
depressive symptoms rather than antidepressant 
treatment were the reason for changes in body weight. 
Analyses were based on antidepressant prescription, 
but non-adherence might be common and could 
diminish estimated associations.26 However, clinical 
trials in depressed patients show that antidepressant 
treatment is associated with weight gain.14 The 
strong temporal association between initiation 
of antidepressant treatment and weight gain also 
suggests a causal association. This dataset reflects 
prescribing habits over a decade. During this time a 
switch occurred from older tricyclic antidepressants 
to selective serotonin reuptake inhibitors (SSRIs) and 
serotonin and noradrenaline reuptake inhibitors. 
Older generation drugs, including monoamine oxidase 
inhibitors and tricyclic antidepressants, are generally 
more associated with weight gain than are the 
newer SSRIs, but the older generation drugs are only 
infrequently prescribed. Associations with weight gain 
might depend on drug dose, but it was not possible to 
reconstruct dosage information for this study.
Comparison with other studies
A systematic review analysed short term studies 
and estimated weight increases over eight months’ 
follow-up.14 Another study evaluated weight gain up 
to two years using electronic health records,15 with 
estimates consistent with a 2.1 kg weight gain with 
fluoxetine treatment and about a 4.8 kg increase with 
setraline. These figures suggest that increases of ≥5% 
body weight are plausible. Our study adds to previous 
data by providing longer follow-up (up to 10 years) 
of antidepressant treatment, showing that the risk of 
weight gain is increased for at least the first five years 
of treatment. Our study also adds a comparison with a 
general population sample that was not treated with 
antidepressant drugs, showing an association between 
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Fig 3 | Adjusted rate ratios (95% confidence intervals) 
for ≥5% weight gain by antidepressant type. Rate ratios 
were adjusted for sex, body mass index category, 
age, age2, diabetes, coronary heart disease, stroke, 
cancer, depression, smoking status, coprescribing of 
antiepileptics or antipsychotics, diet advice, year, region, 
and fifth of deprivation. SNRI=serotonin-noradrenaline 
(norepinephrine) reuptake inhibitors; SSRI=selective 
serotonin reuptake inhibitors; TCA=tricyclic and related 
antidepressants
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Fig 4 | Scatter plot of adjusted rate ratios for ≥5% 
weight gain by number of prescriptions. Rate ratios 
were adjusted for sex, body mass index category, 
age, age2, diabetes, coronary heart disease, stroke, 
cancer, depression, smoking status, coprescribing of 
antiepileptics or antipsychotics, diet advice, year, region, 
and fifth of deprivation. SNRI=serotonin-noradrenaline 
(norepinephrine) reuptake inhibitors; SSRI=selective 
serotonin reuptake inhibitors; TCA=tricyclic and related 
antidepressants
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antidepressant use and transitions to overweight and 
obesity. Weight gain is a well recognised side effect of 
antipsychotic treatment,27 but prescribing guidelines 
generally devote less attention to weight management 
in the context of antidepressant treatment.28 Obesity 
and depression are common, often coexist, and are 
associated with physical comorbidity and worse 
health outcomes.5 Researchers have observed that 
the negative perceptions associated with either a 
depression diagnosis or an obesity diagnosis may 
be potentiated when the conditions overlap.29 This 
makes weight management and obesity prevention 
particularly important in this population. The relation 
between depression symptoms and health behaviours 
that might contribute to weight gain is also a relevant 
concern.30
From a population perspective, these results suggest 
that the widespread use of antidepressants might be 
an important factor contributing to increasing body 
weight. These results should be set in the context of 
increasing BMI in the general population. Data from 
the health survey for England show that between 
2004 and 2014 the prevalence of obesity in adults 
increased from 23% to 26%, and mean BMI increased 
from 26.9 to 27.2.3 From a clinical perspective, 
these observations reinforce the need for active body 
weight management to accompany antidepressant 
treatment,31 although this might often be met with 
limited success. The potential for weight gain may 
also be a consideration in the selection of individual 
antidepressant drugs.
Conclusions and policy implications
Initiation of antidepressant drugs shows a strong 
temporal association with weight gain, which is 
greatest during the second and third years of treatment. 
During the second year of treatment, the risk of 
≥5% weight gain is 46.3% higher than in a general 
population comparison group. These associations 
are consistent across a wide range of clinical, social, 
and demographic characteristics. The increasingly 
widespread use of antidepressants is of concern in the 
context of the increasing prevalence of obesity.
Rates of antidepressant use and obesity are rising simultaneously in 
the UK. The results of this study show that the two phenomena are 
closely linked and that the greatest risk of a ≥5% weight gain occurs 
during the second and third years of treatment and remains elevated 
for up to six years after initiation of treatment (see supplementary 
infographic).
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